Fortis Advisors’s Usana Health Sciences USNA Stock Holding History

Fortis Advisors’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,383	Closed	-$195K	–	320
2020 Q1	$195K	Buy	3,383 +127	+4%	+$8.83K	0.13%	77
2019 Q4	$256K	Hold	3,256	–	–	0.15%	88
2019 Q3	$223K	Buy	+3,256	New	+$219K	0.1%	113
2018 Q1	–	Sell	-1,720	Closed	-$127K	–	324
2017 Q4	$127K	Buy	1,720 +119	+7%	+$7.96K	0.08%	111
2017 Q3	$92K	Buy	+1,601	New	+$94.6K	0.06%	131

Other funds holding USNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fortis Advisors's USNA Position: Q2 2020 in Review

Fortis Advisors sold out of Usana Health Sciences (USNA) in Q2 2020, closing a stake of 3,383 shares — an estimated $195K sold.

Fortis Advisors first reported a position in USNA in Q3 2017 and held it in 5 quarters. The position peaked at $256K in Q4 2019. 192 funds tracked by Wall St. Rank hold USNA as of Q2 2020.

Fortis Advisors reported no remaining Usana Health Sciences position as of Q2 2020 after selling out during the quarter.
Fortis Advisors sold 3,383 Usana Health Sciences shares in Q2 2020, an estimated $195K.
Fortis Advisors first reported a position in Usana Health Sciences in Q3 2017 and held it in 5 quarters.
Fortis Advisors's Usana Health Sciences position peaked at $256K in Q4 2019.
192 funds tracked by Wall St. Rank held Usana Health Sciences as of Q2 2020.

Based on Fortis Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.